| Literature DB >> 32005839 |
Toshiaki Takahashi1, Ryoko Murayama2,3, Mari Abe-Doi2, Maki Miyahara-Kaneko4, Chiho Kanno4, Miwa Nakamura5, Mariko Mizuno5, Chieko Komiyama5, Hiromi Sanada6,7.
Abstract
Peripheral intravenous catheter failure is a significant concern in the clinical setting. We investigated the effectiveness of care protocols, including an ultrasonographic "pre-scan" for selecting a large-diameter vein before catheterization, a "post-scan" for confirming the catheter tip position after catheterization with ultrasonography, and the use of a flexible polyurethane catheter to reduce the mechanical irritation that contributes to the incidence of catheter failure. This intervention study was a non-randomized controlled trial to investigate the effectiveness of the abovementioned care protocols, the effects of which were compared to the outcomes in the control group, which received conventional care. For both groups, participants were selected from patients in two wards at the University of Tokyo in Japan between July and November 2017. Inverse probability score-based weighted methods (IPW) using propensity score were used to estimate the effectiveness of care protocols. The primary outcome was catheter failure, which was defined as accidental and unplanned catheter removal. We used Kaplan-Meier survival curves to compare rates of time until catheter failure. We analysed 189 and 233 catheters in the intervention and control groups, respectively. In the control group, 68 catheters (29.2%) were determined to have failed, whereas, in the intervention group, only 21 catheters (11.1%) failed. There was a significant difference between each group regarding the ratio of catheter failure adjusted according to IPW (p = 0.003). The relative risk reduction of the intervention for catheter failure was 0.60 (95% CI: 0.47-0.71). Care protocols, including assessment of vein diameter, vein depth, and catheter tip location using ultrasound examination for reducing mechanical irritation is a promising method to reduce catheter failure incidence.Entities:
Mesh:
Year: 2020 PMID: 32005839 PMCID: PMC6994694 DOI: 10.1038/s41598-019-56873-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flowchart of the subjects.
Characteristics of participants unadjusted and adjusted using IPW (weighted by inverse probability of propensity score).
| Unadjusted | Adjusted | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control group | Intervention group | Control group | Intervention group | |||||||
| 233 | 189 | |||||||||
| Sex | 0.39 | 0.48 | ||||||||
| Male | 162 | (69.5) | 124 | (65.6) | (65.9) | (68.9) | ||||
| Age (years) | 66.4 | ± 15.9 | 65.2 | ± 14.3 | 0.40 | 65.7 | ± 15.9 | 64.4 | ± 14.3 | 0.21 |
| BMI | 23.1 | ± 3.4 | 22.9 | ± 4.1 | 0.51 | 23.1 | ± 3.3 | 22.8 | ± 4.3 | 0.36 |
| Present illness (tumour) | ||||||||||
| Tumour | 96 | (41.2) | 121 | (64.0) | 0.00* | (47.4) | (53.0) | 0.11† | ||
| Present illness (each organ) | 0.59 | 0.51 | ||||||||
| Gastroenterology | 62 | (26.6) | 50 | (26.5) | (25.3) | (28.6) | ||||
| Hepatobiliary Pancreatic | 153 | (65.7) | 129 | (68.3) | (68.4) | (66.1) | ||||
| Other | 18 | (7.7) | 10 | (5.3) | (6.3) | (5.3) | ||||
| Diabetes | 39 | (16.7) | 44 | (23.3) | 0.09 | (19.5) | (19.8) | 0.93 | ||
| Oral medicine (anticoagulant) | 35 | (15.0) | 26 | (13.8) | 0.76 | (13.3) | (12.6) | 0.79 | ||
| Oral medicine (steroid) | 8 | (3.4) | 12 | (6.3) | 0.21 | (5.3) | (4.8) | 0.75 | ||
| Chemotherapy | 10 | (4.3) | 10 | (5.3) | 0.63 | (5.0) | (4.8) | 0.87 | ||
| Radiation | 1 | (0.4) | 1 | (0.5) | 0.88 | (0.3) | (0.2) | 0.97 | ||
| The level of need for nursing (Kangodo) | 0.18 | 0.15 | ||||||||
| A1 | 1 | (0.4) | 2 | (1.1) | (0.8) | (0.7) | ||||
| A2 | 4 | (1.7) | 2 | (1.1) | (1.8) | (0.7) | ||||
| A3 | 4 | (1.7) | 2 | (1.1) | (1.8) | (2.2) | ||||
| A4 | 1 | (0.4) | 0 | (0.0) | (0.3) | (0.0) | ||||
| B1 | 19 | (8.2) | 13 | (6.9) | (8.3) | (12.7) | ||||
| B2 | 5 | (2.1) | 8 | (4.2) | (3.3) | (3.1) | ||||
| B3 | 108 | (46.4) | 70 | (37.0) | (41.5) | (32.5) | ||||
| B4 | 51 | (21.9) | 38 | (20.1) | (22.6) | (23.7) | ||||
| C1 | 0 | (0.0) | 0 | (0.0) | (0.0) | (0.0) | ||||
| C2 | 0 | (0.0) | 0 | (0.0) | (0.0) | (0.0) | ||||
| C3 | 2 | (0.9) | 5 | (2.6) | (1.5) | (1.7) | ||||
| C4 | 38 | (16.3) | 49 | (25.9) | (18.3) | (22.7) | ||||
| Blood examination | ||||||||||
| C-reactive protein | 2.81 | ± 4.7 | 1.08 | ± 2.5 | 0.00* | 2.2 | ± 4.1 | 1.7 | ± 3.4 | 0.08† |
| Albumin | 3.5 | ± 0.7 | 3.8 | ± 0.7 | 0.00* | 3.6 | ± 0.7 | 3.5 | ± 1.7 | 0.19† |
| Platelet | 21.8 | ± 10.9 | 20.4 | ± 9.2 | 0.20 | 21.2 | ± 11.2 | 21.0 | ± 9.3 | 0.75 |
| Insertion side | 0.70 | 0.74 | ||||||||
| Right | 124 | (53.2) | 92 | (48.7) | (49.4) | (48.2) | ||||
| Dressing films | 0.03* | 0.88† | ||||||||
| IV®3000® | 217 | (93.1) | 187 | (98.9) | (95.5) | (95.7) | ||||
| Tegadearm®1648 | 16 | (6.9) | 2 | (1.1) | (4.5) | (4.3) | ||||
| Level of nurse | 0.00* | 0.14† | ||||||||
| Beginner | 155 | (66.5) | 88 | (46.6) | (60.9) | (54.2) | ||||
| Intermediate | 34 | (14.6) | 82 | (43.4) | (22.3) | (27.0) | ||||
| Expert | 44 | (18.9) | 19 | (10.1) | (16.8) | (18.9) | ||||
| Number of catheterizations | 0.00* | 0.01* | ||||||||
| Once | 123 | (52.8) | 155 | (82.0) | (64.7) | (73.4) | ||||
| Twice | 110 | (47.2) | 34 | (18.0) | (35.3) | (26.6) | ||||
| Pharmacologic factor | ||||||||||
| Hyperosmotic | 53 | (22.7) | 21 | (11.1) | 0.00* | (18.8) | (20.0) | 0.24† | ||
| Antibacterial | 145 | (62.2) | 128 | (67.7) | 0.17 | (64.2) | (60.6) | 0.30 | ||
| Lipid solution | 4 | (1.7) | 2 | (1.1) | 0.53 | (1.3) | (0.7) | 0.44 | ||
| Total rocking time (unused time) | 37.3 | ± 43.5 | 45.4 | ± 37.2 | 0.05* | 41.5 | ± 47.3 | 44.0 | ± 38.2 | 0.40 |
Data are expressed as n (%) ± SD. PIVC, peripheral intravenous catheterization; ND, no data
*p < 0.05; †disappear of significant difference after adjustment.
Level of nurse experience; beginner, 0–100 PIVCs; intermediate, 101–800 PIVCs; expert, 801 + PIVCs.
Figure 2Kaplan-Meier survival curve of time weighted with inverse probability of propensity score. The censor was defined as “removal of catheter after completion of treatment required”.
Characteristics of participants (n = 422) and univariate analysis results on catheter failure.
| Catheter failure (n = 89) | Complete to treat (n = 333) | ||
|---|---|---|---|
| Sex (male) | 55 (61.8) | 231 (69.4) | <0.18 |
| Age (years) | 66.9 ± 18.6 | 65.6 ± 14.2 | <0.48 |
| BMI | 23.5 ± 03.7 | 22.9 ± 03.7 | <0.16 |
| Present illness | |||
| Tumour | 33 (37.1) | 184 (55.3) | <0.01* |
| Each organ | <0.86 | ||
| Gastroenterology | 24 (27.0) | 088 (26.4) | |
| Hepatobiliary/pancreatic | 58 (65.2) | 224 (67.3) | |
| Others | 070 (7.9) | 0210 (6.3) | |
| Diabetes | 16 (18.0) | 067 (20.1) | <0.65 |
| Oral medicine | |||
| Anticoagulant | 11 (12.4) | 050 (15.0) | <0.53 |
| Steroid | 020 (2.2) | 0180 (5.4) | <0.21 |
| Chemotherapy | 060 (6.7) | 0140 (4.2) | <0.22 |
| Radiation | 000 (0.0) | 0020 (0.6) | <0.46 |
| Level of need for nursing (Kangodo) | <0.11 | ||
| A1 | 000 (0.0) | 003 0(0.9) | |
| A2 | 020 (2.2) | 0040 (1.2) | |
| A3 | 020 (2.2) | 0040 (1.2) | |
| A4 | 000 (0.0) | 0010 (0.3) | |
| B1 | 10 (11.2) | 022 0(6.6) | |
| B2 | 050 (5.6) | 0080 (2.4) | |
| B3 | 43 (48.3) | 135 (40.5) | |
| B4 | 17 (19.1) | 072 (21.6) | |
| C1 | 000 (0.0) | 0000 (0.0) | |
| C2 | 000 (0.0) | 0000 (0.0) | |
| C3 | 000 (0.0) | 0070 (2.1) | |
| C4 | 10 (11.2) | 077 (23.1) | |
| Blood examination | |||
| C-reactive protein (mg/dl) | 03.5 ± 04.6 | 01.6 ± 03.7 | <0.01* |
| Albumin (mg/dl) | 03.4 ± 00.7 | 03.7 ± 00.7 | <0.01* |
| Platelet (104/μl) | 22.7 ± 10.8 | 20.8 ± 10.0 | <0.11 |
| Insertion side | |||
| Right | 43 (48.3) | 158 (47.4) | <0.88 |
| Dressing films | <0.90 | ||
| IV®3000® | 040 (4.5) | 0140 (4.2) | |
| Tegaderm®1648 | 85 (95.5) | 319 (95.8) | |
| Level of nurse experience | <0.72 | ||
| Beginner | 48 (53.9) | 195 (58.6) | |
| Intermediate | 26 (29.2) | 090 (27.0) | |
| Expert | 15 (16.9) | 048 (14.4) | |
| Number of catheterizations | <0.01* | ||
| First | 44 (49.4) | 234 (70.3) | |
| Second or more | 45 (50.6) | 099 (29.7) | |
| Total unused time (locked time) | 31.3 ± 39.5 | 43.5 ± 41.3 | <0.01* |
| Insertion anatomical site | <0.01* | ||
| Forearm | 74 (83.1) | 315 (94.6) | |
| Upper arm | 060 (6.7) | 0140 (4.2) | |
| Hand | 080 (9.0) | 0080 (2.4) | |
| Others | 010 (1.1) | 0010 (0.3) | |
| Dominant vein | <0.01* | ||
| Cephalic | 50 (56.2) | 241 (72.4) | |
| Medial cubital | 13 (14.6) | 038 (11.4) | |
| Basilic | 10 (11.2) | 040 (12.0) | |
| Others | 16 (18.0) | 0140 (4.2) | |
| Successes at first catheterization attempts | 56 (62.9) | 239 (71.8) | <0.11 |
| Unsuccessful | 33 (37.1) | 094 (28.2) | |
| Pharmacologic factor | |||
| Hyperosmotic | 33 (37.1) | 041 (12.3) | <0.01* |
| Antibacterial | 52 (58.4) | 221 (66.4) | <0.20 |
| Lipid solution | 030 (3.4) | 0030 (0.9) | <0.08 |
Data are presented as n (%) or mean ± SD. *p < 0.05.
Level of nurse experience: beginner, 0–100 PIVCs; intermediate, 101–800 PIVCs; expert, 801 + PIVCs.
BMI, body mass index; PIVC, peripheral intravenous catheter.
Multiple logistic regression models for risk factors associated with catheter failure (n = 422).
| Model 1 | Model 2 | Model 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | (95% CI) | OR | (95% CI) | OR | (95% CI) | ||||
| Age, 0.1 year | 1.00 | (0.99–1.07) | 0.63 | 1.00 | (0.98–1.02) | 0.97 | 1.001 | (0.98–1.02) | 0.97 |
| Sex, male | 0.63 | (0.39–1.07) | 0.09 | 0.73 | (0.42–1.26) | 0.25 | 0.682 | (0.42–1.26) | 0.25 |
| BMI, 0.1 | 1.05 | (0.98–1.02) | 0.15 | 1.05 | (0.98–1.12) | 0.14 | 1.054 | (0.98–1.12) | 0.14 |
| Care bundle intervention | 0.30 | (0.17–0.51) | 0.01* | 0.36 | (0.20–0.64) | 0.01* | 0.357 | (0.20–0.64) | 0.01* |
| Hyperosmolar solutions | 3.12 | (1.74–5.57) | 0.01* | ||||||
| C-reactive protein, 0.1 mg/dL | 1.06 | (1.00–1.12) | 0.04* | 1.06 | (1.00–1.12) | 0.05* | |||
| Total un-used time (rocked time), 0.1 h | 0.99 | (0.99–1.00) | 0.09 | 0.992 | (0.99–1.00) | 0.03* | |||
| Insertion anatomical site (compared with another site) | 4.17 | (1.79–9.70) | 0.01* | 4.081 | (1.76–9.45) | 0.01* | |||
| Number of catheterizations | 1.462 | (0.85–2.50) | 0.17 | ||||||
| Nagelkerke, R2 | 0.09 | 0.22 | 0.18 | ||||||
Hierarchical multiple logistic regression analysis was performed. Model 1 included age, sex, BMI, and care bundle intervention. Model 2 included Model 1 and hyperosmolar solutions, C-reactive protein, total un-used time, and insertion anatomical site (compared with another site). Model 3 included Model 1 and C-reactive protein, total unused time, and insertion anatomical site (compared with another site) and number of catheterizations.
OR: odds ratio. Model 3: Hosmer-Lemeshow test, p = 0.603.
Multiple logistic regression models for intervention items with catheter failure.
| Model 1 | Model 2 | Model 3 | Model 4 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | |||||
| Age (0.1 year) | 1.01 | (0.99–1.03) | 0.47 | 1.00 | (0.98–1.03) | 0.55 | 1.00 | (0.98–1.03) | 0.69 | 1.01 | (0.98–1.03) | 0.70 |
| Sex (Male) | 0.74 | (0.35–1.53) | 0.41 | 0.73 | (0.35–1.54) | 0.41 | 0.70 | (0.33–1.49) | 0.36 | 0.70 | (0.33–1.49) | 0.36 |
| BMI (0.1) | 1.04 | (0.96–1.13) | 0.34 | 1.04 | (0.96–1.13) | 0.33 | 1.06 | (0.97–1.15) | 0.21 | 1.06 | (0.97–1.15) | 0.22 |
| Hyperosmolar solutions | 3.82 | (1.65–8.83) | 0.01* | 3.78 | (1.65–8.64) | 0.01* | 3.42 | (1.48–7.91) | 0.01* | 3.39 | (1.46–7.86) | 0.01* |
| C-reactive protein (0.1 mg/dL) | 1.03 | (0.95–1.11) | 0.54 | 1.01 | (0.94–1.09) | 0.76 | 0.99 | (0.92–1.07) | 0.88 | 0.99 | (0.92–1.07) | 0.87 |
| Polyurethane catheter | 0.60 | (0.25–1.42) | 0.24 | 0.88 | (0.34–2.24) | 0.78 | ||||||
| Ultrasonography assisted | 0.38 | (0.18–0.80) | 0.01* | 0.39 | (0.18–0.87) | 0.02* | ||||||
| Nagelkerke R2 | 0.092 | 0.097 | 0.127 | 0.128 | ||||||||
Hierarchical multiple logistic regression analysis was performed. Model 1 included age, sex, BMI, hyperosmolar solutions.
C-reactive protein. Model 2 included Model 1 and using polyurethane catheter. Model 3 included Model 1 and ultrasonography assist. Model 4 included all variables.
LL, lower limit; UL, upper limit; OR, odds ratio. Model 4: Hosmer-Lemeshow test, p = 0.19.
Figure 3Diagram of using catheter flow in the intervention group.
Figure 4Definitions of measurement items in ultrasonographic images. (A) showed a short-axis ultrasonographic image of a vein with an inserted PIVC tip (arrow head). White arrows indicate the major and minor axis lengths. Vessel diameter was defined as [major axis + minor axis]/2. The major axis was the longest diameter. The minor axis was perpendicular to the major axis. Black arrows indicate depth defined as [distance from the skin surface to the nearest wall of vessel]. (B) showed schematic diagram of short axis image. Appropriate catheter tip position was defined as the location in the lower side or at the centre of the vein without being attached to the vessel wall (dashed circle). (C) showed a typical case that is no-good in post-scan. Normally, the catheter should lie along the blood vessel, but in this case it is lifted to the skin side. In such a state, mechanical stimulation is particularly enhanced. As a result, the catheter tip position is subject to adjustment. Abbreviation: PIVC, peripheral intravenous catheter.